GeneVentiv Therapeutics

GeneVentive Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders, developing the first AAV-based gene therapy for hemophilia patients with inhibitors. GeneVentiv's lead cadidate has received FDA Orphan Drug Designation.